Mary Ann Liebert Inc
+1
1557-7716
Continuously
6.6
1523-0864
1999
9147402100
United States
English
YES
Google Scholar
cksen@iu.edu
Antioxidants & Redox Signaling (ARS) is the leading peer-reviewed journal dedicated to understanding the vital impact of oxygen and oxidation-reduction (redox) processes on human health and disease. The Journal explores key issues in genetic, pharmaceutical, and nutritional redox-based therapeutics. Cutting-edge research focuses on structural biology, stem cells, regenerative medicine, epigenetics, imaging, clinical outcomes, and preventive and therapeutic nutrition, among other areas. ARS has expanded to create two unique foci within one journal: ARS Discoveries and ARS Therapeutics. ARS Discoveries (24 issues) publishes the highest-caliber breakthroughs in basic and applied research. ARS Therapeutics (12 issues) is the first publication of its kind that will help enhance the entire field of redox biology by showcasing the potential of redox sciences to change health outcomes.
Interleukin-33 (IL-33) acts as an 'alarmin', and its role has been demonstrated in driving immune regulation and inflammation in many human diseases. However, the precise mechanism of action...
OJSCloud offers a complete, free setup to get you publishing.
Start Your Free Journal!Scholar9.com is a peer-review platform that hosts journals from across the globe. Please note that we do not own any of the journals hosted on the platform.
Our platform enables journal owners to send articles for peer review to users who have registered via https://scholar9.com/register and have consented to serve as reviewers for multiple journals. Additionally, we offer an indirect manuscript submission system for journals that are claimed and actively managed by their respective owners on Scholar9.com.
For accurate information about the indexing status of journals (in databases such as UGC CARE, Scopus, or Web of Science) and contact details, users must refer to the respective official websites.
Scholar9 is not responsible for indexing claims, manuscript acceptance/rejection, refunds of article processing charges, or any stage of the final publication process. Users are strongly advised to verify all information provided on the platform independently.
Scholar9.com disclaims liability for disputes related to indexing claims, publication decisions, or other journal-specific matters. Users are encouraged to contact the respective journal owners directly for detailed information and clarifications.